News · 26 weeks570%
2026-04-192026-10-11
Mix2590d
- Insider9(36%)
- SEC Filings7(28%)
- Earnings3(12%)
- Analyst3(12%)
- Other2(8%)
- Leadership1(4%)
Latest news
25 items- ANALYSTBarclays initiated coverage on Boston Scientific with a new price targetBarclays initiated coverage of Boston Scientific with a rating of Equal Weight and set a new price target of $48.00
- SECSEC Form 8-K filed by Boston Scientific Corporation8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- PRBoston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating OfficerNew operating structure designed to increase efficiency and support continued growthMARLBOROUGH, Mass., Oct. 7, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced the appointment of Joseph M. Fitzgerald to executive vice president and chief operating officer (COO), effective Jan. 1, 2027. In this role, Fitzgerald will oversee the company's global operations, business units and regions.In connection with Fitzgerald's appointment, Boston Scientific will establish three reportable segments* — Interventional Therapies, Rhythm Solutions and MedSurg also effective Jan. 1. As the company continues to grow and expand its portfolio, the structure is designed to enable faste
- PRElutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility and SimpliDerm® divestitureThe Company is now fully funded through the first year of the expected NXT-41x launch and into 2029 GAITHERSBURG, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced it has received the full $8 million held in escrow in connection with the sale of its BioEnvelope business to Boston Scientific Corporation (NYSE:BSX). The payment was m
- SECBoston Scientific Corporation filed SEC Form 8-K: Leadership Update8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- ANALYSTBoston Scientific downgraded by Citigroup with a new price targetCitigroup downgraded Boston Scientific from Buy to Neutral and set a new price target of $50.00
- SECSEC Form 8-K filed by Boston Scientific Corporation8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- INSIDERSEC Form 4 filed by Boston Scientific Corporation4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERDirector Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- SECBoston Scientific Corporation filed SEC Form 8-K: Other Events8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- INSIDERSEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERSEC Form 4 filed by EVP and CFO Monson Jonathan4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- PRBoston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 resultsMARLBOROUGH, Mass., Aug. 10, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will participate in Wells Fargo's 21st Annual Healthcare Conference on Thursday, September 10, 2026. Mike Mahoney, chairman and chief executive officer, and Kenneth Stein, M.D., senior vice president and global chief medical officer, will participate in a 35-minute question-and-answer session with the host analyst at approximately 8:00 a.m. ET. Additionally, the company will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2026, on Wednesday, October 28, 2026, at 8:
- INSIDERDirector Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific CorporationSCHEDULE 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)
- INSIDERDirector Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERChairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERSEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERDirector Ludwig Edward J bought $227,400 worth of shares (5,000 units at $45.48), increasing direct ownership by 20% to 30,359 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- SECSEC Form 10-Q filed by Boston Scientific Corporation10-Q - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- ANALYSTBoston Scientific downgraded by ArgusArgus downgraded Boston Scientific from Buy to Hold
- PRPenumbra, Inc. Reports Second Quarter 2026 Financial ResultsALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026. Revenue of $390.0 million in the second quarter of 2026, an increase of 14.9% compared to the second quarter of 2025.Global thrombectomy revenue of $259.0 million in the second quarter of 2026, an increase of 12.5% compared to the second quarter of 2025.Global embolization and access revenue of $131.1 million in the second quarter of 2026, an increase of 20.0% compared to the second quarter of 2025.Gross profit margin of 67.9% in the seco
- SECBoston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- PRBoston Scientific announces results for second quarter 2026MARLBOROUGH, Mass., July 29, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational1 and organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $907 million or $0.61 per share (EPS), compared to $797 million or $0.53 per share a year ago, and achieved adjusted3 EPS of $0.86 for the period, compared to $0.75 a year ago. "Our team delivered a solid quarter while continuing to navigate a
- SECBoston Scientific Corporation filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
BSX FAQ
6 questionsWhat does Boston Scientific Corporation do?
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also...Where does BSX stock trade?
Boston Scientific Corporation (BSX) is listed on NYSE.What sector and industry is BSX in?
Boston Scientific Corporation operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about BSX?
Boston Scientific Corporation has had 8 recent analyst actions on file. The most recent action was from Barclays: Equal Weight with a $4800.00 price target on 2026-10-07. Recent price targets cluster around $4800.00.What companies are similar to BSX?
Notable peers in the same industry include JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MDT (Medtronic plc.), SYK (Stryker Corporation), BDX (Becton Dickinson and Company). Compare BSX side-by-side with any of them on Quantisnow.How can I track BSX on Quantisnow?
Quantisnow aggregates Boston Scientific Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BSX to receive live email and push alerts on every new disclosure.